Literature DB >> 34287029

Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review.

Aaron T Ciner1, Howard S Hochster1, David A August1, Darren R Carpizo2, Kristen R Spencer1.   

Abstract

Aim: Cytokine release syndrome (CRS) is an infrequently described immune-related adverse event of checkpoint inhibitors (CPI). CPI-induced CRS typically presents with fevers, hemodynamic instability and organ dysfunction within 2 weeks of the last treatment cycle. Case study: We report an unusual case of delayed and severe CRS occurring postoperatively in a patient with hepatic-limited metastatic colorectal cancer who received neoadjuvant immunotherapy. After a negative workup for alternative causes, he received prolonged corticosteroid treatment with symptom resolution.
Conclusion: CPI-induced CRS can mimic sepsis and clinicians should maintain a high-index of suspicion to diagnose this immune-related adverse event early and initiate appropriate treatment. As use of perioperative immunotherapy increases, the potential role of surgery to trigger CRS in this case warrants further investigation.

Entities:  

Keywords:  colorectal cancer; cytokine release syndrome; immunotherapy; neoadjuvant treatment; surgical-induced inflammation

Mesh:

Substances:

Year:  2021        PMID: 34287029      PMCID: PMC8656293          DOI: 10.2217/imt-2020-0329

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.040


  40 in total

1.  Severe cytokine release syndrome in a patient receiving PD-1-directed therapy.

Authors:  Seth J Rotz; Daniel Leino; Sara Szabo; Jennifer L Mangino; Brian K Turpin; Joseph G Pressey
Journal:  Pediatr Blood Cancer       Date:  2017-05-24       Impact factor: 3.167

Review 2.  IL-6 and APPs: anti-inflammatory and immunosuppressive mediators.

Authors:  H Tilg; C A Dinarello; J W Mier
Journal:  Immunol Today       Date:  1997-09

Review 3.  Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy.

Authors:  Noelle Frey; David Porter
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-23       Impact factor: 5.742

4.  Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma.

Authors:  Alexandra E Foran; Helen R Nadel; Anna F Lee; Kerry J Savage; Rebecca J Deyell
Journal:  J Pediatr Hematol Oncol       Date:  2017-07       Impact factor: 1.289

5.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

6.  Comparison of interleukin-6, interleukin-8, and granulocyte colony-stimulating factor production by the peritoneum in laparoscopic and open surgery.

Authors:  N Yahara; T Abe; K Morita; A Tangoku; M Oka
Journal:  Surg Endosc       Date:  2002-06-27       Impact factor: 4.584

Review 7.  Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.

Authors:  David Porter; Noelle Frey; Patricia A Wood; Yanqiu Weng; Stephan A Grupp
Journal:  J Hematol Oncol       Date:  2018-03-02       Impact factor: 17.388

8.  Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database.

Authors:  Alessandro Ceschi; Roberta Noseda; Karine Palin; Katia Verhamme
Journal:  Front Pharmacol       Date:  2020-05-04       Impact factor: 5.810

9.  First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer.

Authors:  Hiroyasu Oda; Mikiya Ishihara; Yoshihiro Miyahara; Junko Nakamura; Yuji Kozuka; Motoh Iwasa; Akira Tsunoda; Yoshiki Yamashita; Kanako Saito; Toshiro Mizuno; Hiroshi Shiku; Naoyuki Katayama
Journal:  Case Rep Oncol       Date:  2019-02-08

Review 10.  Potential impact of invasive surgical procedures on primary tumor growth and metastasis.

Authors:  Maria Alieva; Jacco van Rheenen; Marike L D Broekman
Journal:  Clin Exp Metastasis       Date:  2018-05-04       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.